Shareholders in Molecular Data (NASDAQ:MKD) have lost 71%, as stock drops 17% this past week

By
Simply Wall St
Published
August 16, 2021
NasdaqCM:MKD
Source: Shutterstock

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But it's not unreasonable to try to avoid truly shocking capital losses. So we hope that those who held Molecular Data Inc. (NASDAQ:MKD) during the last year don't lose the lesson, in addition to the 71% hit to the value of their shares. That'd be a striking reminder about the importance of diversification. We wouldn't rush to judgement on Molecular Data because we don't have a long term history to look at. Shareholders have had an even rougher run lately, with the share price down 40% in the last 90 days.

Since Molecular Data has shed CN¥15m from its value in the past 7 days, let's see if the longer term decline has been driven by the business' economics.

View our latest analysis for Molecular Data

Molecular Data wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Molecular Data's revenue didn't grow at all in the last year. In fact, it fell 42%. That's not what investors generally want to see. The market obviously agrees, since the share price tanked 71%. That's a stern reminder that profitless companies need to grow the top line, at the very least. But markets do over-react, so there opportunity for investors who are willing to take the time to dig deeper and understand the business.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
NasdaqCM:MKD Earnings and Revenue Growth August 17th 2021

If you are thinking of buying or selling Molecular Data stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Given that the market gained 35% in the last year, Molecular Data shareholders might be miffed that they lost 71%. While the aim is to do better than that, it's worth recalling that even great long-term investments sometimes underperform for a year or more. The share price decline has continued throughout the most recent three months, down 40%, suggesting an absence of enthusiasm from investors. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. It's always interesting to track share price performance over the longer term. But to understand Molecular Data better, we need to consider many other factors. Even so, be aware that Molecular Data is showing 5 warning signs in our investment analysis , and 2 of those don't sit too well with us...

But note: Molecular Data may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you’re looking to trade Molecular Data, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted


Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.